Amaury Daste

2.3k total citations
66 papers, 848 citations indexed

About

Amaury Daste is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Amaury Daste has authored 66 papers receiving a total of 848 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 19 papers in Otorhinolaryngology. Recurrent topics in Amaury Daste's work include Cancer Immunotherapy and Biomarkers (30 papers), Head and Neck Cancer Studies (19 papers) and Cancer Diagnosis and Treatment (11 papers). Amaury Daste is often cited by papers focused on Cancer Immunotherapy and Biomarkers (30 papers), Head and Neck Cancer Studies (19 papers) and Cancer Diagnosis and Treatment (11 papers). Amaury Daste collaborates with scholars based in France, United States and Spain. Amaury Daste's co-authors include Alain Ravaud, Marine Gross‐Goupil, Charlotte Domblides, Amandine Quivy, Pierre Soubeyran, Camille Chakiba, Caroline Even, Christophe Le Tourneau, J. Guigay and Erwan de Monès and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Amaury Daste

59 papers receiving 840 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amaury Daste France	13	610	279	173	173	167	66	848
Lara Alessandrini Italy	17	284 0.5×	199 0.7×	136 0.8×	82 0.5×	237 1.4×	69	827
Xiao-Jing Du China	8	497 0.8×	194 0.7×	164 0.9×	103 0.6×	145 0.9×	9	677
L.L. Siu Canada	10	833 1.4×	290 1.0×	54 0.3×	179 1.0×	247 1.5×	30	1.1k
Orit Gutfeld Israel	12	266 0.4×	110 0.4×	244 1.4×	30 0.2×	288 1.7×	24	630
Abdul R. Fakih India	11	373 0.6×	141 0.5×	372 2.2×	120 0.7×	285 1.7×	26	704
Linda Feeley Ireland	14	291 0.5×	71 0.3×	214 1.2×	86 0.5×	230 1.4×	38	670
Su Jung Shim South Korea	14	294 0.5×	156 0.6×	110 0.6×	50 0.3×	303 1.8×	34	819
A. Psyrri Greece	9	300 0.5×	193 0.7×	225 1.3×	42 0.2×	197 1.2×	23	814
Christopher Y. Thomas United States	13	366 0.6×	147 0.5×	112 0.6×	29 0.2×	483 2.9×	21	826
Keita Kudo Japan	13	1.0k 1.7×	611 2.2×	17 0.1×	193 1.1×	122 0.7×	35	1.3k

Countries citing papers authored by Amaury Daste

Since Specialization

Citations

This map shows the geographic impact of Amaury Daste's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amaury Daste with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amaury Daste more than expected).

Fields of papers citing papers by Amaury Daste

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amaury Daste. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amaury Daste. The network helps show where Amaury Daste may publish in the future.

Co-authorship network of co-authors of Amaury Daste

This figure shows the co-authorship network connecting the top 25 collaborators of Amaury Daste. A scholar is included among the top collaborators of Amaury Daste based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amaury Daste. Amaury Daste is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matitashvili, Amiran, Hua Wang, Hsuan‐Cheng Huang, et al.. (2025). 1325MO Retifanlimab (Anti–PD-1 mAb) alone or in combination with Anti-LAG3 ± Anti-TIM3 mAbs In previously untreated, recurrent and/or metastatic (R/M) PD-L1+ HNSCC: A double-blind randomised controlled phase II trial. Annals of Oncology. 36. S772–S772.

Soulières, Denis, Yi‐Chun Liu, Kedar Kirtane, et al.. (2025). LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 36. S1592–S1592.

Tourneau, C. Le, C. Even, Assuntina G. Sacco, et al.. (2024). 411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial. Annals of Oncology. 35. S1557–S1558. 2 indexed citations

Fayette, Jérôme, Gerald A. Thomas, Amaury Daste, et al.. (2024). 853MO Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial. Annals of Oncology. 35. S615–S616. 4 indexed citations

Fayette, Jérôme, Florian Clatot, Irene Braña, et al.. (2024). Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 6014–6014. 12 indexed citations

Collet, L., Christian Borel, Magalie P. Tardy, et al.. (2023). Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study. BMC Cancer. 23(1). 663–663. 3 indexed citations

Bossi, Paolo, Irene Braña, Víctor Moreno, et al.. (2023). 362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC). Annals of Oncology. 34. S1610–S1611. 5 indexed citations

Daste, Amaury, et al.. (2023). Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives. Immunotherapy. 16(3). 187–197. 12 indexed citations

Tourneau, Christophe Le, Frédéric Rolland, Olivier Capitain, et al.. (2023). Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.. Journal of Clinical Oncology. 41(16_suppl). 2630–2630.

10.

Durand, Sylvère, Matthieu Texier, Amaury Daste, et al.. (2022). Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors. OncoImmunology. 12(1). 2150472–2150472. 1 indexed citations

11.

Saleh, Khalil, Anne Aupérin, Nicolas Martin, et al.. (2021). Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. European Journal of Cancer. 157. 190–197. 10 indexed citations

12.

Larroquette, Mathieu, Charlotte Domblides, Amandine Quivy, et al.. (2021). Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. European Journal of Cancer. 158. 47–62. 53 indexed citations

13.

Daste, Amaury, Anderson Loundou, Florent Peyraud, et al.. (2021). Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. Cancer Medicine. 10(12). 3952–3963. 11 indexed citations

14.

Argiris, Athanassios, Kevin J. Harrington, Makoto Tahara, et al.. (2021). LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651. Annals of Oncology. 32. S1310–S1311. 21 indexed citations

15.

Cho, Byoung Chul, Amaury Daste, Alain Ravaud, et al.. (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. Journal for ImmunoTherapy of Cancer. 8(2). e000664–e000664. 69 indexed citations

16.

Gross‐Goupil, Marine, Charlotte Domblides, Vincent Pointillart, et al.. (2018). Treatment of spinal metastases in renal cell carcinoma: A critical review. Critical Reviews in Oncology/Hematology. 125. 19–29. 12 indexed citations

17.

Daste, Amaury, Charlotte Domblides, Marine Gross‐Goupil, et al.. (2017). Immune checkpoint inhibitors and elderly people: A review. European Journal of Cancer. 82. 155–166. 139 indexed citations

18.

Gross‐Goupil, Marine, et al.. (2017). Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature. Clinical Genitourinary Cancer. 15(5). e885–e887. 2 indexed citations

19.

Daste, Amaury, et al.. (2016). Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Clinical Genitourinary Cancer. 14(5). e525–e527. 1 indexed citations

20.

Daste, Amaury, et al.. (2013). Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature. Targeted Oncology. 9(1). 81–84. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact